NASDAQ: CBIOCrescent Biopharma Inc Stock
$17.69-0.52 (-2.86%)
Updated Jun 18, 2026
CBIO Price
$17.69
Fair Value Price
$19.90
Market Cap
$487.75M
52 Week Low
$8.72
52 Week High
$27.41
P/E
-1.5x
P/B
2.65x
P/S
51.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.84M
Earnings
-$162.08M
Gross Margin
100%
Operating Margin
-1,466.29%
Profit Margin
-1,494.6%
Debt to Equity
0.08
Operating Cash Flow
-$75M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CBIO Overview
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CBIO
Ranked#91 of 465
Ranked#91 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important CBIO news, forecast changes, insider trades & much more!
CBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBIO ($17.69) is undervalued by 11.12% relative to our estimate of its Fair Value price of $19.90 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CBIO ($17.69) is not significantly undervalued (11.12%) relative to our estimate of its Fair Value price of $19.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CBIO due diligence checks available for Premium users.
Valuation
CBIO fair value
Fair Value of CBIO stock based on Discounted Cash Flow (DCF)
Price
$17.69
Fair Value
$19.90
Undervalued by
11.12%
CBIO ($17.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBIO ($17.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.5x
Industry
15.77x
Market
9.47x
CBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.65x
Industry
4.95x
CBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.3M
Profit Margin
0%
CBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$199.1M
Liabilities
$15.3M
Debt to equity
0.08
CBIO's short-term assets ($195.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBIO's short-term assets ($195.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
-$8.1M
Financing
-$6.9M
CBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBIO vs Biotech Stocks
Crescent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.